Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective

In recent years the incretin therapies have provided a new treatment option for patients with type 2 diabetes mellitus (T2DM). The incretin therapies focus on the increasing levels of the two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). T...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Dominique Xavier, Evans, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483791/
https://www.ncbi.nlm.nih.gov/pubmed/23125920
http://dx.doi.org/10.1155/2012/381713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483791/
https://www.ncbi.nlm.nih.gov/pubmed/23125920
http://dx.doi.org/10.1155/2012/381713

Ejemplares similares